氘丁苯那嗪治疗单侧下肢肌肉僵硬的迟发性运动障碍报道
桂林市精神卫生中心, 精三科, 广西桂林 541001
| 摘 要： | 病史摘要：患者，性别：男，32岁，因“服用抗精神病药物一年余出现右下肢跨步式走路”于2023年10月15日到我院专家门诊就诊，曾多次到广西及多省大医院就诊，均未见好转，在北京知名综合医院检查肌肉及神经系统未见异常，于2025年3月17日再次到我院专家门诊就诊。症状体征：意识清晰，定向力完整，接触良好，未引出精神症状。神经系统未见明显异常，右侧下肢膝关节以下肌肉僵硬，肌张力增高，不能伸直。导致右侧下肢跨步式走路。诊断方法：病人服用抗精神病药物利培酮半年后出现运动障碍，在北京综合医院排除肌肉神经系统疾病。符合迟发性运动障碍诊断，即应用抗精神病药物6个月后出现运动障碍。治疗方案：考虑病人就诊过程及诊断结果，目前对迟发性运动障碍明确有效的为氘丁苯那嗪片剂。根据其服药方法和体质，采用小剂量开始缓慢递增方案。临床转归：病人经过四周的药物治疗后，右侧下肢肌张力恢复如常，恢复正常走路。随访一个月后病情稳定。目前维持服药治疗中。 |
| 关 键 词： | 氘丁苯那嗪; 单侧肌肉僵硬; 迟发性运动障碍 |
| DOI： | 10.57237/j.cmf.2026.01.002 |
View:
Downloads:
收稿日期: 2026-04-12
接受日期: 2026-05-07
在线出版日期: 2026-05-13
Report on the Treatment of Delayed-onset Dystonia Characterized by Muscle Rigidity in the Single Lower Limb with Deuterobenzoyl Benzhexazine
Department 3, Guilin Mental Health Center, Guilin 541001, China
| Abstract: | Medical History Abstract: Patient, male, 32 years old, presented to our expert outpatient clinic on October 15, 2023, due to “progressive right-leg gait after more than a year of taking antipsychotic medication.” The patient had previously visited numerous large hospitals in Guangxi and other provinces, but there had been no improvement. Examination of the muscles and nervous system at a prominent Beijing comprehensive hospital revealed no abnormalities. The patient returned to our expert outpatient clinic on March 17, 2025. Symptoms and findings: Conscious and oriented, normal contact, no signs of mental symptoms. No significant abnormalities in the nervous system. Muscles below the knee in the right leg were stiff, with increased muscle tone, preventing straightening. This resulted in a gait resembling a stride-and-pause pattern. Diagnosis: The patient developed movement disorders six months after starting antipsychotic medication (risperidone). A comprehensive examination at a Beijing hospital ruled out muscle and nervous system disorders. The diagnosis was consistent with tardive dyskinesia, characterized by the onset of movement disorders six months or more after initiating antipsychotic treatment. Treatment Plan: Based on the patient’s medical history and diagnosis, the most effective treatment for tardive dyskinesia currently available is deutetrabenazine tablets. Starting with a low dose and gradually increasing the dosage over time was recommended, taking into account the patient’s medication regimen and overall health. Clinical Outcome: After four weeks of treatment, the patient’s muscle tone in the right leg returned to normal, and he was able to walk normally again. Follow-up one month later showed that the condition remained stable. The patient continues to receive treatment. |
| Keywords: | Deuterobenzoyl Benzhexazine; Unilateral Muscle Rigidity; Tardive Dyskinesia |
参考文献
| [1] | 王喜喜, 万新华. 迟发性运动障碍的临床诊治进展 [J]. 协和医学杂志, 2022, 13(4): 644-651. |
| [2] | 袁俊亮, 谭云龙, 王强, 石川, 王刚, 吴仁荣, 胡少华, 万新华, 刘铁榜, 商慧芳, 陈海波, 司天梅, 于欣. 迟发性运动障碍的诊疗研究进展 [J]. 中华精神医学杂志, 2024, 57(2): 121~128. |
| [3] | CARBON M, HSIEH C H, KANE J M, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis [J]. J Clin Psychiatry, 2017, 78(3): e264-e278. |
| [4] | 马俊, 万新华. 迟发性运动障碍的研究进展 [J]. 中华老年心脑血管病杂志, 2017, 19(11): 1227-1230. |
| [5] | 刘登堂, 司天梅, 况利, 王强, 郑英君, 黄满丽, 江开达. 氘丁苯那嗪治疗迟发性运动障碍的指导建议 [J]. 中国神经精神疾病杂志, 2025, 51(2): 65-71. |
| [6] | 于婷, 范丰梅, 李艳丽, 杨贵刚, 谭淑平, 王志仁, 杨甫德, 周东丰, 谭云龙. 伴发迟发性运动障碍精神分裂症患者大脑皮质形态学磁共振成像研究 [J]. 中国心理卫生杂志. 2017, 31(7): . 518-522. |
| [7] | 鲁成好, 李申, 张晓菲. 精神分裂症患者迟发性运动障碍基因多态性的研究进展 [J]. 临床精神医学杂志. 2025. 35(2): 157-160. |
| [8] | 孙莉, 蔡丽丽, 黄光彪 . 氘丁苯那嗪治疗抗精神病药引起的迟发性运动障碍1例 [J]. 中华精神医学杂志. 2022, 55(2) : 142-144 |
| [9] | 中华医学会神经病学分会帕金森病及运动障碍学组. 肌张力障碍治疗中国专家共识 [J]. 中华神经科杂志, 2020, 53(11): 868-874. |
| [10] | 陆颖, 孙扬, 朱丽萍. 迟发性运动障碍的机制和治疗进展 [J]. 精神医学杂志, 2017, 30(3): 237-240. |
| [11] | Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018 Jun 15; 389: 67-75. |
| [12] | Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017; 4(8): 595-604. |
| [13] | Hauser RA, Barkay H, Fernandez HH, et al. Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. Front Neurol. 2022;13: 773999. Published 2022 Feb 23. |
| [14] | Liu Y, et al. Antipsychotic Plasma Concentration as Predictor of Movement Disorders and Cardiometabolic Side-Effects: A Comparison with Prescription Dose. 2026 SIRS Abstract Book. T274. |
| [15] | 袁俊亮教授: CSP 2025迟发性运动障碍新进展《中国迟发性运动障碍的队列研究 (TDChina)》. |
